Table 3.

Data of hyperglycaemic type 2 diabetic vs healthy volunteers

	Age (years)	BMI	Gender	Glucose (mM)
Healthy volunteers mean (n=8)±s.e.mean	62.3±2.4	28.6±1.9	5M/3F	5.72±0.22
Diabetic patients mean (n=10)±s.e.mean	69.0±4.0	33.5±3.0	4M/6F	10.28±1.17***

Abbreviations: BMI, body mass index, expressed in kg m⁻²; F, female; M, male.

We used patients with type 2 diabetes with randomized pharmacological treatments. In fact, of the 10 patients, two were under treatment with metformin, one with metformin + insulin, one with glibenclamide, two with metformin+glibenclamide, one with acarbose+glibenclamide and three with insulin only. In each case, the last treatment was given not later than 12 h before blood sampling. As shown in the Table, this heterogeneity in treatment resulted in similar fasting glycaemia values. ^***P<0.005 vs healthy volunteers, as assessed by the Kruskal–Wallis nonparametric test. BMI, body mass index, expressed in kg m⁻².